(Q44564587)

English

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

scientific article published in September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma (English)

1 reference

Europe PubMed Central

4 December 2017

Francisco J Esteva

1

1 reference

Europe PubMed Central

4 December 2017

Gabriel N Hortobagyi

9

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

4 December 2017

author name string

Edgardo Rivera

2

1 reference

Europe PubMed Central

4 December 2017

Massimo Cristofanilli

3

1 reference

Europe PubMed Central

4 December 2017

Vicente Valero

4

1 reference

Europe PubMed Central

4 December 2017

Melanie Royce

5

1 reference

Europe PubMed Central

4 December 2017

Anil Duggal

6

1 reference

Europe PubMed Central

4 December 2017

Philippe Colucci

7

1 reference

Europe PubMed Central

4 December 2017

Robert DeJager

8

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

98

1 reference

Europe PubMed Central

4 December 2017

5

1 reference

Europe PubMed Central

4 December 2017

900-907

1 reference

Europe PubMed Central

4 December 2017

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

DX-8951f: summary of phase I clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumour activity of DX-8951f: a new camptothecin derivative.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11557

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11557

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44564587&oldid=2028164514"